Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences
Cadrenal Therapeutics (NASDAQ: CVKD) has announced its participation in several key medical and business development conferences during Q2 2025. The company, which is developing tecarfarin, a Phase 3-ready oral vitamin K antagonist anticoagulant, will be represented at:
- 18th National Conference on Anticoagulation Therapy in Washington, D.C. (April 3-5)
- 13th annual CMO Summit 360° ® (April 7-8)
- BIO International Convention in Boston, MA (June 16-19)
Chief Operating Officer Jeff Cole and Chief Medical Officer Dr. James Ferguson will attend these events to engage with industry experts, key opinion leaders, and potential partners to advance tecarfarin development and build their specialized cardiovascular therapeutics pipeline.
Cadrenal Therapeutics (NASDAQ: CVKD) ha annunciato la sua partecipazione a diverse importanti conferenze mediche e di sviluppo commerciale durante il secondo trimestre del 2025. L'azienda, che sta sviluppando tecarfarin, un anticoagulante antagonista della vitamina K pronto per la fase 3, sarà rappresentata a:
- 18ª Conferenza Nazionale sulla Terapia Anticoagulante a Washington, D.C. (3-5 aprile)
- 13° Summit annuale CMO 360° ® (7-8 aprile)
- Convenzione Internazionale BIO a Boston, MA (16-19 giugno)
Il Direttore Operativo Jeff Cole e il Direttore Medico Dr. James Ferguson parteciperanno a questi eventi per interagire con esperti del settore, leader di opinione e potenziali partner per promuovere lo sviluppo di tecarfarin e costruire il loro pipeline di terapie cardiovascolari specializzate.
Cadrenal Therapeutics (NASDAQ: CVKD) ha anunciado su participación en varias conferencias clave de desarrollo médico y empresarial durante el segundo trimestre de 2025. La compañía, que está desarrollando tecarfarin, un anticoagulante antagonista de la vitamina K listo para la fase 3, estará representada en:
- 18ª Conferencia Nacional sobre Terapia Anticoagulante en Washington, D.C. (3-5 de abril)
- 13° Cumbre Anual CMO 360° ® (7-8 de abril)
- Convención Internacional BIO en Boston, MA (16-19 de junio)
El Director de Operaciones Jeff Cole y el Director Médico Dr. James Ferguson asistirán a estos eventos para interactuar con expertos de la industria, líderes de opinión clave y posibles socios para avanzar en el desarrollo de tecarfarin y construir su cartera de terapias cardiovasculares especializadas.
카드레날 제약 (NASDAQ: CVKD)는 2025년 2분기 동안 여러 주요 의료 및 비즈니스 개발 회의에 참여한다고 발표했습니다. 이 회사는 3상 준비가 완료된 경구 비타민 K 길항제 항응고제인 테카르파린을 개발하고 있으며, 다음 회의에 참석할 예정입니다:
- 워싱턴 D.C.에서 열리는 제18회 항응고 치료 국가 회의 (4월 3-5일)
- 제13회 연례 CMO 서밋 360° ® (4월 7-8일)
- 보스턴 MA에서 열리는 BIO 국제 컨벤션 (6월 16-19일)
운영 책임자 제프 콜과 의료 책임자 제임스 퍼거슨 박사가 이 행사에 참석하여 업계 전문가, 주요 의견 리더 및 잠재적 파트너와 소통하여 테카르파린 개발을 촉진하고 전문 심혈관 치료 파이프라인을 구축할 예정입니다.
Cadrenal Therapeutics (NASDAQ: CVKD) a annoncé sa participation à plusieurs conférences clés en matière de développement médical et commercial au cours du deuxième trimestre 2025. L'entreprise, qui développe le tecarfarin, un anticoagulant oral antagoniste de la vitamine K prêt pour la phase 3, sera représentée lors des événements suivants :
- 18ème Conférence Nationale sur la Thérapie Anticoagulante à Washington, D.C. (3-5 avril)
- 13ème Sommet Annuel CMO 360° ® (7-8 avril)
- Convention Internationale BIO à Boston, MA (16-19 juin)
Le Directeur des Opérations Jeff Cole et le Directeur Médical Dr. James Ferguson assisteront à ces événements pour échanger avec des experts du secteur, des leaders d'opinion clés et des partenaires potentiels afin de faire avancer le développement du tecarfarin et de construire leur pipeline de thérapies cardiovasculaires spécialisées.
Cadrenal Therapeutics (NASDAQ: CVKD) hat seine Teilnahme an mehreren wichtigen medizinischen und geschäftlichen Entwicklungskonferenzen im zweiten Quartal 2025 angekündigt. Das Unternehmen, das tecarfarin, ein für Phase 3 bereitstehendes orales Vitamin-K-Antagonisten-Antikoagulans, entwickelt, wird vertreten sein bei:
- 18. Nationalkonferenz zur Antikoagulationstherapie in Washington, D.C. (3.-5. April)
- 13. jährlicher CMO Summit 360° ® (7.-8. April)
- BIO Internationale Konvention in Boston, MA (16.-19. Juni)
Der Chief Operating Officer Jeff Cole und der Chief Medical Officer Dr. James Ferguson werden an diesen Veranstaltungen teilnehmen, um sich mit Branchenexperten, wichtigen Meinungsführern und potenziellen Partnern auszutauschen, um die Entwicklung von tecarfarin voranzutreiben und ihre spezialisierte Pipeline für kardiovaskuläre Therapien auszubauen.
- None.
- None.
Management Available for One-to-One Meetings
Chief Operating Officer, Jeff Cole and Chief Medical Officer, Dr. James Ferguson will represent the Company at the 18th National Conference on Anticoagulation Therapy in
Additionally, Dr. Ferguson will attend the 13th annual CMO Summit 360° ® taking place on April 7-8, the largest gathering of biotech Chief Medical Officers across indications, modalities, company stages, professional experience levels, and geographic locations.
Expanding its industry and business development engagement, the Company will be at the BIO International Convention, the world’s largest biotechnology conference, from June 16-19, 2025 in
About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development of tecarfarin, a new Phase 3-ready oral vitamin K antagonist anticoagulant to address unmet needs in anticoagulation therapy. Tecarfarin is a novel, and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation. Although warfarin is widely used off-label for several rare cardiovascular conditions, extensive clinical and real-world data have shown it to have significant serious side effects. With tecarfarin, Cadrenal aims to meet the unmet needs of these patient populations by relieving them and their healthcare providers of some of warfarin’s greatest clinical challenges.
Cadrenal is pursuing a product-in-a-pipeline approach with tecarfarin. Tecarfarin received Orphan Drug designation (ODD) for advanced heart failure patients with implanted mechanical circulatory support devices, including Left Ventricular Assisted Devices (LVADs). The Company also received ODD and fast-track status for tecarfarin in end-stage kidney disease and atrial fibrillation (ESKD+AFib).
Cadrenal is opportunistically pursuing business development initiatives with a longer-term focus to build a pipeline of specialized cardiovascular therapeutics. For more information, visit www.cadrenal.com and connect with us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250403821539/en/
Corporate and Investor Relations
Lisa DeScenza
LaVoieHealthScience
(978) 395-5970
ldescenza@lavoiehealthscience.com
Media
Andrew Korda
LaVoieHealthScience
(617) 865-0043
akorda@lavoiehealthscience.com
Source: Cadrenal Therapeutics, Inc.
FAQ
What conferences will Cadrenal Therapeutics (CVKD) attend in Q2 2025?
What is the main product being developed by Cadrenal Therapeutics (CVKD)?
Who will represent CVKD at these conferences?
What is the purpose of CVKD's participation in the BIO International Convention 2025?
